Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005-2013.


Journal

Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234

Informations de publication

Date de publication:
07 2019
Historique:
received: 28 02 2019
revised: 18 03 2019
accepted: 30 04 2019
pubmed: 29 5 2019
medline: 21 4 2020
entrez: 29 5 2019
Statut: ppublish

Résumé

The UK IBD Audit Programme reported improved inpatient care processes for ulcerative colitis (UC) between 2005 and 2013. There are no independent data describing national or institutional trends in patient outcomes over this period. To assess the association between the outcome of emergency admission for UC and year of treatment. Retrospective analysis of hospital administrative data, focused on all emergency admissions to English public hospitals with a discharge diagnosis of UC. We extracted case mix factors (age, sex, co-morbidity, emergency bed days in last year, deprivation status), outcomes of index admission (death and first surgery), 30-day emergency readmissions (all-cause, and selected causes) and outcome of readmission. There were 765 deaths and 3837 unplanned first operations in 44 882 emergency admissions, with 5311 emergency readmissions (with a further 171 deaths and 517 first operations). Case mix adjusted odds of death for any given year were 9% lower (OR 0.91, 95% CI: 0.89-0.94), and that for emergency surgery 3% lower (OR 0.97, 95% CI: 0.95-0.98) than the preceding year. Results were robust to sensitivity analysis (admissions lasting ≥4 days). There was no reduction in odds for all-cause readmission, but rates for venous thromboembolism declined significantly. Analysis of institutional-level metrics across 136 providers showed a stepwise reduction in outliers for mortality and unplanned surgery. Risk of death and unplanned surgery for UC patients admitted as emergencies declined consistently, as did unexplained variation between hospitals. Risk of readmission was unchanged (over 1 in 10). Multiple factors are likely to explain these nationwide trends.

Sections du résumé

BACKGROUND
The UK IBD Audit Programme reported improved inpatient care processes for ulcerative colitis (UC) between 2005 and 2013. There are no independent data describing national or institutional trends in patient outcomes over this period.
AIM
To assess the association between the outcome of emergency admission for UC and year of treatment.
METHODS
Retrospective analysis of hospital administrative data, focused on all emergency admissions to English public hospitals with a discharge diagnosis of UC. We extracted case mix factors (age, sex, co-morbidity, emergency bed days in last year, deprivation status), outcomes of index admission (death and first surgery), 30-day emergency readmissions (all-cause, and selected causes) and outcome of readmission.
RESULTS
There were 765 deaths and 3837 unplanned first operations in 44 882 emergency admissions, with 5311 emergency readmissions (with a further 171 deaths and 517 first operations). Case mix adjusted odds of death for any given year were 9% lower (OR 0.91, 95% CI: 0.89-0.94), and that for emergency surgery 3% lower (OR 0.97, 95% CI: 0.95-0.98) than the preceding year. Results were robust to sensitivity analysis (admissions lasting ≥4 days). There was no reduction in odds for all-cause readmission, but rates for venous thromboembolism declined significantly. Analysis of institutional-level metrics across 136 providers showed a stepwise reduction in outliers for mortality and unplanned surgery.
CONCLUSIONS
Risk of death and unplanned surgery for UC patients admitted as emergencies declined consistently, as did unexplained variation between hospitals. Risk of readmission was unchanged (over 1 in 10). Multiple factors are likely to explain these nationwide trends.

Identifiants

pubmed: 31135073
doi: 10.1111/apt.15315
pmc: PMC6617780
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-192

Subventions

Organisme : Crohn's and Colitis UK
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Références

Gastrointest Endosc. 2011 Oct;74(4):825-33
pubmed: 21835401
Am J Gastroenterol. 2007 Mar;102(3):609-17
pubmed: 17156150
Intest Res. 2019 Jan;17(1):45-53
pubmed: 30449081
BMC Gastroenterol. 2012 Jun 26;12:79
pubmed: 22734919
Br Med Bull. 2006 Jul 17;75-76:131-44
pubmed: 16847166
Gut. 2012 Oct;61(10):1410-6
pubmed: 22684482
BMJ. 2007 Nov 17;335(7628):1033
pubmed: 17977817
J Crohns Colitis. 2017 Oct 27;11(11):1362-1368
pubmed: 28961891
Can J Gastroenterol Hepatol. 2016;2016:8723949
pubmed: 28074174
Gut. 2014 Feb;63(2):250-61
pubmed: 23426895
Gut. 2011 Jan;60(1):130-3
pubmed: 21030524
Stat Med. 2005 Apr 30;24(8):1185-202
pubmed: 15568194
J Crohns Colitis. 2018 Mar 28;12(4):408-418
pubmed: 29216349
J Am Coll Surg. 2010 Apr;210(4):390-401
pubmed: 20347730
BMJ Open. 2018 Feb 21;8(2):e017195
pubmed: 29467130
J Crohns Colitis. 2019 Jan 1;13(1):127-137
pubmed: 30423033
BMJ. 2007 May 19;334(7602):1044
pubmed: 17452389
Aliment Pharmacol Ther. 2016 Feb;43(4):482-513
pubmed: 26725569
Intern Med J. 2019 Jul;49(7):859-866
pubmed: 30525299
N Engl J Med. 2017 Oct 19;377(16):1551-1558
pubmed: 29045205
Aliment Pharmacol Ther. 2019 Jul;50(2):176-192
pubmed: 31135073
Mil Med Res. 2018 Feb 8;5(1):5
pubmed: 29502532
Aliment Pharmacol Ther. 2018 Apr;47(7):913-921
pubmed: 29411411
Inflamm Bowel Dis. 2017 Mar;23(3):347-356
pubmed: 28221246
Frontline Gastroenterol. 2013 Oct;4(4):296-301
pubmed: 28839740

Auteurs

Mustafa Shawihdi (M)

Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Susanna Dodd (S)

Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Constantinos Kallis (C)

Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Pete Dixon (P)

Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Ruth Grainger (R)

Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Stuart Bloom (S)

Gastrointestinal Service, University College London Hospital, London, UK.

Fraser Cummings (F)

Gastroenterology Unit, University Hospital Southampton NHS Trust, Southampton, UK.

Mike Pearson (M)

Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Keith Bodger (K)

Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Digestive Diseases Centre, Aintree University Hospital NHS Trust, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH